# Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy

> **NCT05753618** · PHASE4 · RECRUITING · sponsor: **Ottawa Hospital Research Institute** · enrollment: 242 (estimated)

## Conditions studied

- Early-stage Breast Cancer

## Interventions

- **DRUG:** Granulocyte Colony-Stimulating Factor (G-CSF)
- **DRUG:** Omission of Granulocyte Colony-Stimulating Factor (G-CSF)

## Key facts

- **NCT ID:** NCT05753618
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-17
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 242 (ESTIMATED)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05753618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05753618, "Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05753618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*